Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status—A Real-World Analysis in Patients With Advanced NSCLC

David J. Cantor, Halla Nimeiri, L. Horn, Matthew West, Rotem Ben‐Shachar, Iker Huerga, Jyoti D. Patel, Charu AggarwalClinical 2025 · DOI

BibTeX
@inproceedings{cantor2025outcomes,
  author = {David J. Cantor and Halla Nimeiri and L. Horn and Matthew West and Rotem Ben‐Shachar and Iker Huerga and Jyoti D. Patel and Charu Aggarwal},
  title = {{Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status—A Real-World Analysis in Patients With Advanced NSCLC}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1016/j.cllc.2025.05.007},
}

Loading related content...

Figure